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Abstract
Objective Neurological symptoms of COVID-19 patients have been recently described. However, no comprehensive data 
have been reported on pre-existing neurological comorbidities and COVID-19. This study aims at evaluating the prevalence 
of neurological comorbidities, and their association with COVID-19 severity.
Methods We evaluated all consecutive patients admitted to the Emergency Room (ER) of our hospital between the 3rd 
March and the 14th April 2020, and diagnosed with COVID-19. Data on neurological and non-neurological diseases were 
extracted, as well as data on demographic characteristics and on severity degree of COVID-19. The prevalence of neurologi-
cal comorbidities was calculated, and multivariate binary logistic regression analyses were used to estimate the association 
between neurological diseases and COVID-19 severity.
Results We included 344 patients. Neurological comorbidities accounted for 22.4% of cases, with cerebrovascular diseases 
and cognitive impairment being the most frequent. Neurological comorbidity resulted independently associated with severe 
COVID-19 (OR 2.305; p = 0.012), as well as male gender (p = 0.001), older age (p = 0.001), neoplastic diseases (p = 0.039), 
and arterial hypertension (p = 0.045). When neurological comorbidity was associated with non-neurological comorbidities, 
the OR for severe COVID-19 rose to 7.394 (p = 0.005). Neurological patients, in particular cerebrovascular and cognitively 
impaired ones, received more respiratory support indication.
Conclusion Neurological comorbidities represent a significant determinant of COVID-19 severity, deserving a thorough 
evaluation since the earliest phases of infection. The vulnerability of patients affected by neurological diseases should sug-
gest a greater attention in targeting this population for proactive viral screening.
Keywords COVID-19 · Neurology · Stroke · Cerebrovascular disease · Dementia
Introduction
Coronavirus disease 2019 (COVID-19) is an infectious dis-
ease caused by severe acute respiratory syndrome corona-
virus-2 (SARS-CoV-2), declared a pandemic on 11 March 
2020 [1]. Clinical features range from the absence of symp-
toms to severe respiratory failure [2]. A rapidly increasing 
number of  articles have been published on COVID-19, 
including numerous reports and studies on associated neu-
rological symptoms and complications [3], such as acute 
stroke [4], hyposmia [5], Guillain–Barrè syndrome [6], 
encephalitis [7]. It has been shown that about one-third of 
COVID-19 patients develop neurological symptoms [3, 8], 
in most cases associated with a more severe infection [3], 
indicating a potential neurotropism of SARS-CoV-2 as one 
of the possible mechanisms of neurological damage [9, 
 * Leonardo Lopiano 
 leonardo.lopiano@unito.it
1 Department of Neuroscience “Rita Levi Montalcini”, 
University of Turin, Via Cherasco 15, 10126 Turin, Italy
2 Section of Clinical Epidemiology, Center for Epidemiology 
and Oncologic Prevention (CPO Piemonte), Città della Salute 
e della Scienza, Turin, Italy
3 Department of Medical Sciences, Front Line 
P.S. P.O. Molinette, Città Della Salute e Della Scienza, Turin, 
Italy
4 Department of Neuroscience, Brighton& Sussex Medical 
School, University of Sussex, Brighton, East Sussex, UK
 Journal of Neurology
1 3
10]. A recent retrospective study reported that inpatients 
from a neurological ward affected by COVID-19 showed 
a worse outcome compared to those infection-free [11]. 
However, no data have been reported yet on the prevalence 
and the association with infection severity of pre-existing 
neurological comorbidities in COVID-19 patients. A scop-
ing review on the occurrence of neurological diseases in 
COVID-19 patients reported a prevalence of about 8% [12]. 
Nevertheless, this review highlighted the methodological 
heterogeneity in the reviewed papers, which limit a reliable 
estimation of prevalence of neurological diseases in COVID-
19 patients, as well as their association with the infection 
severity.
The aim of our study was to evaluate, on a large cohort of 
consecutive patients admitted to the Emergency Room (ER) 
and diagnosed with COVID-19, the prevalence of neurologi-
cal comorbidities and their possible association with a more 
severe form of COVID-19 onset.
Methods
We evaluated all consecutive patients admitted to the ER of 
the “Città della Salute e della Scienza di Torino Hospital” 
between 3 March 2020 and 14 April 2020, and diagnosed 
with COVID-19 by means of a positive Reverse Transcrip-
tion Polymerase Chain Reaction nasopharyngeal swab.
Comorbidities definition
In all patients, we assessed both neurological and non-neuro-
logical comorbidities. A medical condition was attributed to 
the patients when: (a) defined diagnosis, and/or (b) unequiv-
ocal diagnostic test results, and/or (c) specific medical/surgi-
cal treatment, and/or (d) specific follow-up were reported. 
Moreover, previous clinical notes available in our hospital 
electronic archives were reviewed.
The Charlson Comorbidity Index (CCI) [13], defined as 
the sum of the weighted scores of various comorbid condi-
tions (Table 1), was calculated for each patient to grade their 
comorbid conditions.
Infection severity definition
The severity of COVID-19 at the time of admission to ER 
was evaluated by means of the 2007 Infectious Diseases 
Society of America/American Thoracic Society Criteria 
for Defining Severe Community-acquired Pneumonia [14]. 
Severe disease was identified in patients presenting with one 
major criterion or three or more minor criteria (Table 2).
Table 1  Components and relative weights of the Charlson Comorbid-
ity Index
The Charlson Comorbidity Index results by the sum of the various 
comorbidities multiplied by their weight score
Weight Comorbidities
















3 × Moderate/severe liver disease
6 × Metastatic solid tumor
AIDS
Table 2  2007 Infectious Diseases Society of America/American Tho-
racic Society Criteria for Defining Severe Community-acquired Pneu-
monia
A severe form of infection was defined by the presence of either one 
major criterion or three or more minor criteria
BUN blood urea nitrogen; PaO2/FiO2 arterial oxygen pressure/frac-
tion of inspired oxygen, WBC white blood cell
Major criteria
 Septic shock with need for vasopressors
 Invasive mechanical ventilation
Minor criteria
 Respiratory rate ≥ 30 breaths/min
 PaO2/FIO2 ratio ≤ 250
 Multilobar infiltrates
 Confusion/disorientation
 Uremia (BUN level ≥ 20 mg/dl)
 Leukopenia as a result to infection alone (WBC count < 4,000 cells/
ml)
 Thrombocytopenia (platelet count < 100,000/ml)
 Hypothermia (core temperature < 36° C)
 Hypotension requiring aggressive fluid resuscitation
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Discharge from ER definition
Patients’ discharge from the ER was classified as follows
(a) Home: discharge at home with indication to fiduciary 
isolation and health surveillance by the general practi-
tioner;
(b) Internal Medicine Unit without mechanical respiratory 
support: admission to a ward equipped for best medical 
treatment and respiratory support with oxygen mask;
(c) Internal Medicine Unit with non-invasive mechanical 
respiratory support: admission to a ward equipped with 
non-invasive mechanical ventilation for respiratory 
support;
(d) Intensive Care Unit (ICU): admission to a ward 
equipped with invasive mechanical ventilation for res-
piratory support.
Statistical analysis
Descriptive statistics (mean, standard deviation, range) were 
used for continuous variables and frequency for categori-
cal data. The Mann–Whitney test and Fisher’s exact test 
were used for comparisons between groups, as appropri-
ate. A first univariate binary logistic regression was used to 
estimate the odds ratio (OR) of presenting severe infection 
(dependent variable), considering as independent variables 
various demographic and clinical features, including neu-
rological comorbidity. Then, we performed a second, mul-
tivariate, binary logistic regression analysis considering as 
independent variables every feature resulting significantly 
associated with severe infection in the previous univariate 
analysis. Finally, a third binary logistic regression analysis 
was performed, adjusting for age and CCI, considering four 
categories of patients as independent variable: (a) absence 
of any neurological or non-neurological disease (used as 
control group) (b) presence of neurological disease without 
other comorbidities, (c) presence of neurological disease 
plus other comorbidities, and (d) presence of comorbidi-
ties without neurological diseases. The Hosmer and Leme-
show’s goodness-of-fit test was applied. In case of multiple 
comparisons, Bonferroni’s correction was used. All p-values 
reported were two-tailed, and a p < 0.05 was considered sta-
tistically significant. Data were analyzed using the Statistical 
Package for the Social Sciences (SPSS 22 for Mac, Chicago, 
IL).
Ethics
This study received approval from the ethical standards com-
mittee on human experimentation (Comitato Etico Intera-
ziendale AOU Città della Salute e della Scienza di Torino, 
AO Ordine Mauriziano di Torino, ASL Città di Torino; 
Protocol number 00172/2020, approved May 5th, 2020), 
and patients gave their written informed consent.
Results
The main demographic and clinical features of 344 consecu-
tive patients evaluated are summarized in Table 3.
Table 3  Demographic and Clinical features
Results are reported as average ± standard deviation (range) or abso-
lute values (percentage), as appropriate
Gender (males/females) 204/140 (59.3%/40.7%)
Age (years) 61.5 ± 17.8 (15-98)
Time from symptoms onset (days) 6.1 ± 4.4 (0-30)






 Sore throat 5 (1.5%)
 Confusion 4 (1.2%)





 Fever and cough 88 (25.6%)
 Fever and dyspnea 13 (3.8%)
 Fever and diarrhea 10 (2.9%)
 Fever and anosmia 5 (1.5%)
 Cough and dyspnea 5 (1.5%)
 Fever and sore throat 4 (1.2%)
 Three or more symptoms 40 (11.6%)
 Neurological Diseases—N (%) 77 (22.4%)
 Arterial Hypertension—N (%) 158 (45.9%)
 Neoplastic Diseases—N (%) 49 (14.2%)
 Diabetes—N (%) 42 (12.2%)
 Chronic obstructive pulmonary disease—
N (%)
41 (11.9%)
 Renal failure—N (%) 18 (5.2%)
 Charlson Comorbidity Index 2.0 ± 2.5 (0-16)
 Institutionalized patients—N (%) 19 (5.5%)
 Severe infection—N (%) 118 (34.3%)
Discharge from Emergency Room—N (%)
 Home 126 (36.6%)
 Internal Medicine Unit without mechani-
cal respiratory support
170 (49.4%)
 Internal Medicine Unit with non-invasive 
mechanical respiratory support
25 (7.3%)
 Intensive Care Unit 23 (6.7%)
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The mean age of the entire sample was 61.5 years: 4.7% 
of patients were ≤30-year-old, while 33.7% were ≥70-year-
old. Male accounted for 59.3% of cases. The mean latency 
between the symptoms’ onset and the ER admittance was 
6.1 days, ranging from 0 to 30 days; only two patients (0.6%) 
with mild symptoms (sore throat and sporadic cough) had a 
latency of 30 days, while 91.6% of patients were evaluated 
within 10 days from the onset, and 7.8% between 11 and 
15 days. The most frequent symptom at COVID-19 onset 
was fever (74.1%; n = 255; isolated in 100 patients, asso-
ciated with ≥1 other symptoms in 155 patients), followed 
by cough (44.8%; n = 154), dyspnea (13.7%; n = 47), and 
diarrhea (9.3%; n = 32). The majority of patients reported 
a monosymptomatic onset (52.0%; n = 179), while 36.3% 
(n = 125) presented with two symptoms, and 11.6% (n = 40) 
with three or more symptoms. Thirty-four percent of cases 
(n = 118) entered the ER with a severe form of infection.
Arterial hypertension was the most frequent comorbidity 
(45.9%), followed by neurological diseases (22.4%), neo-
plastic diseases (14.2%), diabetes (12.2%), chronic obstruc-
tive pulmonary disease (COPD) (11.9%), and renal failure 
(5.2%).
None of the patients were treated with specific anti-
viral drugs before admission; 9 of them (2.6%) were on 
hydroxychloroquine therapy (200 mg bid; therapy duration 
5.2 ± 2.6 days, range 1–10).
Prevalence and type of neurological diseases
A total of 22.4% of patients (n = 77) showed a neurological 
comorbidity. Compared to patients not affected by neurolog-
ical diseases (Table 4), they were disproportionately over-
represented among the severe COVID-19 (p < 0.001). They 
were older (mean difference 16.2 years; p < 0.001), had a 
shorter interval between symptoms onset and ER admittance 
(mean difference 1.9 days; p = 0.001), and were more fre-
quently affected by hypertension, renal failure, and neoplas-
tic diseases (p≤0.001); their CCI was higher (p < 0.001), 
and they presented a higher prevalence of institutionaliza-
tion (p < 0.001). Pre-existing cerebrovascular diseases were 
the most common comorbidity, affecting 39.0% of patients 
(n = 30/77, including 7 patients with hemorrhagic and 23 
with ischemic stroke), followed by cognitive impairment 
(32.5%, including 4 patients with Mild Cognitive Impair-
ment, 10 with Alzheimer’s Disease or Alzheimer’s Disease-
like dementia, and 11 with vascular dementia), migraine 
or chronic tension-type headache or trigeminal neuralgia 
(14.3%; n = 11), epilepsy (6.5%; n = 5), peripheral neuropa-
thy (5.2%; n = 4), Parkinson disease (1.3%; n = 1), and mul-
tiple sclerosis (1.3%; n = 1).
A minority of patients (18.2%; n = 14) suffered only from 
neurological disease. The remaining 63 patients suffered also 
from one (32.5%; n = 25), two (37.7%; n = 29), or three or 
more (11.7%; n = 9) other comorbidities, with arterial hyper-
tension representing the most frequent comorbidity (90.5% 
of cases), followed by neoplastic diseases (36.5% of cases).
Neurological diseases and infection severity
The univariate binary logistic regression analysis (Table 5) 
revealed that a more severe form of infection was signifi-
cantly associated with the presence of neurological disease 
(OR 5.855; 95% CI 3.387–10.122; p = 0.001), together with 
male gender, arterial hypertension, diabetes, renal failure, 
COPD, neoplastic disease, institutionalization, older age, 
and higher CCI.
On the multivariate binary logistic regression analysis 
(Fig. 1a), the presence of neurological diseases remained 
independently associated with severe infection (OR 
2.305; 95% CI 1.053–5.046; p = 0.012), as well as male 
Table 4  Differences between 
patients with or without 
neurological disease
Results are reported as average ± standard deviation (range) or absolute values (percentage), as appropriate. 
p value: statistical comparison between the two groups







Severe infection – N (%) 51 (66.2%) 67 (25.1%) < .001
Gender (males/females -  %) 37/40 (48.1%/51.9%) 167/100 (62.5%/37.5%) 0.023
Age (years) 74.1 ± 15.9 (30-97) 57.9 ± 16.6 (15-98) < .001
Time from symptoms onset (days) 4.6 ± 3.8 (0-15) 6.5 ± 4.5 (0-30) 0.001
Arterial Hypertension – N (%) 57 (74.0%) 101 (37.8%) < .001
Neoplastic Diseases – N (%) 23 (29.9%) 26 (9.7%) < .001
Diabetes – N (%) 12 (15.6%) 30 (11.2%) 0.305
Chronic Obstructive Pulmonary Disease—N (%) 13 (16.9%) 28 (10.5%) 0.127
Moderate-to-severe renal failure—N (%) 10 (13.0%) 8 (3.0%) 0.001
Charlson comorbidity index 4.3 ± 2.9 (0-16) 1.3 ± 1.8 (0-11) < .001
Institutionalized patients—N (%) 15 (19.5%) 4 (1.5%) < .001
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gender (p = 0.001), older age (p = 0.001), neoplastic diseases 
(p = 0.039), and arterial hypertension (p = 0.045).
After the ER admittance, patients affected by neuro-
logical diseases showed a lower rate of discharge at home 
(15.6% vs. 42.7%; p < 0.001), a higher rate of non-invasive 
mechanical respiratory support (15.6% vs. 4.9%; p = 0.001) 
and intensive care indication (14.3% vs. 4.5%; p = 0.002). 
In contrast, they showed a similar rate of hospitalization 
without the need of mechanical respiratory support (54.5% 
vs. 47.9%; p = 0.307).
After dividing the sample in patients without any comor-
bidities, patients with neurological disease without other 
comorbidities, patients with other comorbidities without 
neurological diseases, and patients with neurological disease 
and other comorbidities, the latter group showed the strong-
est association with a severe COVID-19 (OR 7.394; 95% 
CI 1.840–29.704; p = 0.005), compared with patients with 
neurological (OR 2.332; 95% CI 1.202–6.858; p = 0.035) 
or non-neurological (OR 1.724; 95% CI 1.100–3.790; 
p = 0.041) comorbidity alone (Fig. 1b).
Comparison of infection severity among different 
neurological diseases
The association between neurological comorbidity and 
COVID-19 severity varied among the different neurologi-
cal diseases (Table 6). Patients affected by cerebrovascu-
lar diseases and cognitive impairment showed a higher 
prevalence of severe infection, a lower rate of discharge at 
home and a higher rate of non-invasive mechanical venti-
lation or intensive care indication, significantly different 
from patients without neurological diseases (p < 0.001). 
Conversely, patients affected by headache/facial pain, epi-
lepsy, and peripheral neuropathy did not show any signifi-
cant differences.
Both patients affected by multiple sclerosis and Parkin-
son disease (not shown in Table 6) suffered from severe 
COVID-19 that required hospitalization, without the need 
of mechanical respiratory support.
Discussion
In this study, we evaluated the prevalence of neurologi-
cal pre-existing comorbidities in a large cohort of patients 
admitted to ER and diagnosed with COVID-19, estimat-
ing their association with infection severity. Over 20% of 
patients presented with neurological comorbidities, with 
cerebrovascular disease and cognitive impairment being 
the most frequent. Patients with neurological comorbidity 
showed an OR of 2.3 of suffering from severe COVID-19, 
even after including age and other clinical and demographic 
characteristics in the multivariate analysis. This association 
was stronger when patients suffering from a neurological 
condition in association with other comorbidities were com-
pared to patients with isolated neurological or non-neurolog-
ical diseases. Cerebrovascular diseases and cognitive impair-
ment showed higher rate of severe infection and respiratory 
support indication, and lower rate of discharge at home.
To date, the incidence of new-onset neurological symp-
toms or syndromes associated with COVID-19 has been 
reported [3–8], but the description of the relationship 
between pre-existing neurological comorbidities and infec-
tion severity still lacks. A recent review by Herman and col-
leagues reported a pooled prevalence of neurological comor-
bidities of 8% among 22 reviewed studies (range 0–40%), 
without conclusive data on the association with infection 
severity [12]. A recent study on inpatients from a neuro-
logical ward [11], showed worse clinical and functional out-
comes, a more frequent use of high-flow oxygenation and 
antibiotic/antiviral treatments, longer hospitalization, and 
higher in-hospital mortality rate in patients with neurologi-
cal diseases and COVID-19, compared to patients without 
infection; the vast majority of patients with COVID-19 were 
hospitalized for acute cerebrovascular events. Moreover, a 
meta-analysis reported that pre-existing cerebrovascular 
diseases could be an independent risk factor for COVID-19 
[15]. In small-sample studies, cerebrovascular diseases have 
been associated with more frequent ICU admission [16] and 
with more severe forms of infection [17, 18]. In addition, 
Du and colleagues reported a 2.4-fold higher mortality risk 
in patients with cerebrovascular or cardiovascular disease, 
without specifying the distinction between these two condi-
tions [19].
Table 5  Univariate analysis of association between patients’ charac-
teristics and severe form of infection
Results are reported as Odds Ratio (OR); 95% Confidence Interval is 
reported in brackets. P-value: statistical significance
Demographic and clinical features OR (95% CI)  P 
value
Male gender 1.942 (1.212–3.110) 0.006
Age 1.076 (1.057–1.095) < .001
Time from symptoms onset 0.998 (0.949–1.050) 0.940
Neurological disease 5.855 (3.387–10.122) < .001
Arterial hypertension 4.236 (2.631–6.821) < .001
Neoplastic disease 4.575 (2.413–8.672) < .001
Diabetes 2.950 (1.528–5.696) 0.001
Chronic obstructive pulmonary 
disease
2.497 (1.291–4.830) 0.007
Moderate-to-severe renal failure 5.835 (2.231–10.088) 0.001
Charlson comorbidity index 1.600 (1.408–1.819) < .001
Institutionalization 18.851 (4.275–83.135) < .001
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Table 6  Differences among neurological diseases
Results are reported as absolute values (percentage). p-value: statistical comparison among groups. *: significant difference vs. Patients without 














logical disease (N = 267)
 p value
Severe infection—N (%) 20 (66.7%)* 22 (88.0%)* 3 (27.3%) 2 (40.0%) 2 (50.0%) 67 (25.1%) < .001
Discharge from emergency room—N 
(%)
< .001
Home 4 (13.3%)* 0 (0.0%)* 7 (63.6%) 1 (20.0%) 0 (0.0%) 114 (42.7%)
Internal Medicine Unit without mechan-
ical respiratory support
16 (53.3%) 15 (60.0%) 3 (27.3%) 3 (60.0%) 3 (75.0%) 128 (47.9%)
Internal Medicine Unit with non-inva-
sive mechanical respiratory support
3 (10.0%) 7 (28.0%)* 1 (9.1%) 1 (20.0%) 0 (0.0%) 13 (4.9%)
Intensive Care Unit 7 (23.3%)* 3 (12.0%) 0 (0.0%) 0 (0.0%) 1 (25.0%) 12 (4.5%)
Fig. 1  Multivariate analysis of 
association between patients’ 
characteristics and severe form 
of infection. Odds ratios of 
associations between patients’ 
characteristics and severe form 
of infection. In part b, values are 
adjusted for age and CCI, and 
patients without any comor-
bidities were used as reference 
group. CCI Charlson Comor-
bidity Index, COPD chronic 
obstructive pulmonary disease
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Our data show that patients with pre-existing cerebro-
vascular diseases are more frequently hospitalized, needing 
ICU admission in over 20% of cases, and present with a 
severe infection in two-thirds of cases. We observed similar 
findings in cognitively impaired/demented patients. A recent 
paper reported a prevalence of 6.8% of dementia in a sample 
of 355 Italian patients who died with COVID-19, without 
assessing the association with infection severity [20].
In our samples, we observed that patients suffering 
from neurological diseases were older, more affected by 
other comorbidities, and more institutionalized. Age is a 
frequently reported risk factor for severe COVID-19 [16, 
19], as well as hypertension [21], diabetes [21, 22], neo-
plastic diseases [21, 23], COPD [21], and institutionaliza-
tion [24]. These observations were confirmed in our study. 
The multivariate analysis showed that even correcting for 
age, institutionalization, and comorbidities, the presence of 
neurological diseases seems to be independently associated 
with a more severe form of infection. The strongest associa-
tion with severe COVID-19 was observed in patients with 
both neurological diseases and other comorbidities. This 
finding is consistent with the results reported by Guan and 
colleagues, who found hazard ratios for worse infection 
outcomes as higher as the number of concomitant diseases 
increases [21]. On the other hand, institutionalization, diabe-
tes, renal failure, and COPD showed a high association with 
infection severity only in the univariate analysis, but not in 
the multivariate analysis.
The higher prevalence of severe COVID-19 in patients 
affected by neurological diseases is probably multifacto-
rial. The intrinsic frailty of chronic and often degenerative 
conditions, the older age, and the higher comorbidity bur-
den observed in these patients could certainly explain this 
association [25]. Patients affected by neurological diseases 
could present a lower ability to compensate for COVID-19, 
resulting in more severe infection and higher need of ER 
assistance. Moreover, the potential neurotropism of SARS-
CoV-2, with a possible detrimental effect on pre-existing 
neurological diseases, should also be taken into account [9, 
10], as already postulated during the SARS-CoV epidemic 
in 2003 [26]. While waiting for more accurate pathologi-
cal evidences, our data underline that patients with neuro-
logical diseases, in particular when associated with other 
comorbidities, represent a population at high risk for severe 
COVID-19, needing a careful health surveillance.
Our study presents with some limitations. First, the 
single-center design, which partially restricts the generaliz-
ability of our findings. Second, only a minority of patients 
suffered from neurological diseases without other comor-
bidities, limiting the conclusions on the association between 
neurological pathology alone and severe COVID-19. Third, 
the observations on the prevalence of each neurological dis-
order, and thus the ability to discriminate disease-specific 
associations with COVID-19, are limited by two factors: a) 
the evaluation of patients admitted to ER, which could repre-
sent a selection bias towards older people, and b) the lack of 
adjustments for the relative prevalence of each neurological 
disease in the general population.
In conclusion, our study reports the prevalence of differ-
ent neurological diseases in a large cohort of patients with 
COVID-19, assessing their association with the infection 
severity. In our sample, patients with pre-existing neuro-
logical diseases showed a significantly higher risk for severe 
infection, in particular when associated with other comor-
bidities, suggesting that this population deserves a thorough 
evaluation since the earliest phases of overt or suspected 
COVID-19. Finally, our findings suggest a particular atten-
tion in targeting patients with neurological diseases for pro-
active viral screening.
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